Chugai Pharmaceutical Co., Ltd.: EPS $0.27; revenue $2.56B vs $2.27B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 0.27 | — | — | 0.23 |
| Revenue (USD bn) | 2.56 | 2.27 | +12.5% | 2.26 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Oct 27, 2026 | Q3 FY2026 | 0.27 | — | — | 2.56 | 2.27 | +12.5% |
| Jul 24, 2026 | Q2 FY2026 | 0.22 | — | — | 2.14 | 2.16 | −1.0% |
| Apr 24, 2026 | Q1 FY2026 | 0.22 | — | — | 2.05 | 1.95 | +5.2% |
| Jan 29, 2026 | Q4 FY2025 | 0.25 | — | — | 2.56 | 1.84 | — |
| Oct 24, 2025 | Q3 FY2025 | 0.23 | — | — | 2.26 | 2.06 | +9.6% |
| Jul 24, 2025 | Q2 FY2025 | 0.20 | — | — | 2.00 | 2.20 | −9.0% |
| Apr 24, 2025 | Q1 FY2025 | 0.19 | — | — | 1.98 | 1.82 | +8.8% |
| Jan 30, 2025 | Q4 FY2024 | 0.18 | — | — | 1.92 | 1.87 | +2.5% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures. Figures are in USD as carried for this US-traded line; the company reports in another currency.
Chugai Pharmaceutical Co., Ltd. results: EPS $0.27; revenue $2.56B vs $2.27B. The results cover the company's Q3 FY2026. Revenue above the estimate by 12.5%. Figures are in USD as carried for this US-traded line; the company reports in JPY.
Revenue was up 13.3% from $2.26 billion a year earlier (Q3 FY2025). EPS was up 17.4% from $0.23 a year earlier.
What the results mean
Revenue growth at Chugai Pharmaceutical Co., Ltd. points to an expansion in its pharmaceutical business. However, the available information does not identify the products or markets driving that growth or establish its effect on profitability.
The company combines pharmaceutical research, development, manufacturing, marketing and international trade. Its domestic activities include manufacturing and research and development in Japan, while overseas operations include sales and production in Europe, Taiwan and China. Understanding its performance therefore requires examining market mix, production efficiency and its ability to turn research into commercial products.
What to watch on the earnings call: The earnings call merits attention for management’s explanation of revenue growth drivers, demand across domestic and overseas markets, and how product mix and manufacturing costs affect margins. Research and development spending and its connection to the development of the pharmaceutical business also warrant discussion.
For the full analysis of Chugai Pharmaceutical Co., Ltd. stock — valuation, scores and financial statements — see the stock page linked with this story.